The pathogenic impact of tumor-infiltrating B cells is unresolved at present, however, some studies suggest that they may have immune regulatory potential. Here we report that the microenvironment of various solid tumors includes B cells that express granzyme B (GrB, GZMB), where these B cells can be found adjacent to IL-21-secreting T regulatory cells Together, these findings may stimulate novel diagnostic and cell therapeutic approaches to better manage human cancer as well as autoimmune and graft-versus-host pathologies.
Abstract
The pathogenic impact of tumor-infiltrating B cells is unresolved at present, however, some studies suggest that they may have immune regulatory potential. Here we report that the microenvironment of various solid tumors includes B cells that express granzyme B (GrB, GZMB), where these B cells can be found adjacent to IL-21-secreting T regulatory cells (Tregs) that contribute to immune tolerance of tumor antigens. Because T regs and plasmacytoid dendritic cells are known to modulate T effector cells by a GrB-dependent mechanism, we hypothesized that a similar process may operate to modulate B regulatory cells (B regs ). IL-21 induced outgrowth of B cells expressing high levels of GrB, which thereby limited T cell proliferation by a GrB-dependent degradation of the T cell receptor ζ-chain. Together, these findings may stimulate novel diagnostic and cell therapeutic approaches to better manage human cancer as well as autoimmune and graft-versus-host pathologies.
Mechanistic investigations into how IL-21 activated GrB expression in B cells

Introduction
It is widely recognized that certain B cell subpopulations exhibit potent regulatory properties and are involved in immune pathologies including autoimmune and malignant diseases (1, 2) .
In murine autoimmune models, adoptive B cell transfer can ameliorate chronic inflammatory responses even when the disease is already established (1, 3) . Similarly, in human patients with rheumatoid arthritis, disease activity is lower in patients with high peripheral B cell counts (4) . One of the factors produced by regulatory B cells (B reg ) is the immunosuppressive cytokine IL-10, which has recently been identified in mouse models (1, (5) (6) (7) and humans (1, 2, 8, 9) . Nevertheless, although some clinical observations clearly support the concept of human B cells contributing to the limitation of autoimmune diseases, in other cases they are known to have rather aggravating potential (10) . To better understand the development of regulatory versus pathogenic B cells, a more comprehensive knowledge of factors inducing and mediating regulatory B cell functions is necessary.
A previously discovered cytokine with pleiotropic effects on a variety of immune cells is interleukin 21 (IL-21)(11). The effects of IL-21 on B cells strongly depend on additional signals including TLR agonists, B cell receptor (BCR) stimulation and CD40 ligation(12).
Recently, CD40 ligand (CD40L) was shown to determine whether IL-21 induces differentiation of B cells into plasma cells (13, 14) , or, in its absence, into B cells secreting the serine protease granzyme B (GrB) (15, 16) . Importantly, GrB is characterized not only by its classical function as cytotoxic protease, but also exhibits immunosuppressive properties such as in regulatory T cells (T reg ) (17) (18) (19) and dendritic cells (20) . In line with these findings, IL-21
has been described to mediate expression of IL-10 by murine cytotoxic cells and B cells (21, 22) , supporting its involvement in immune regulation.
Several inflammatory conditions including systemic lupus erythematosus (SLE) and acute viral infections are characterized by both elevated GrB (23, 24) and IL-21 serum levels (15, 25, 26) . Moreover, we recently demonstrated that GrB + B cells can be found in SLE patients (15) and in subjects vaccinated against viral infections (16) . An association of GrB + B cells with solid tumors has not been reported so far. However, while infiltration of certain tumors with B cells can be associated with a good prognosis (27) (28) (29) (30) , in others the presence of B cells support a tumor-protective environment (31) (32) (33) . We therefore hypothesized that GrB-expressing B 
Materials and Methods
Human subjects and cell culture
The use of blood from human subjects was approved by the Ethics Committee at Ulm
University. Blood samples were collected after informed consent had been given. Peripheral blood mononuclear cells (PBMC) or mononuclear cells from umbilical cord blood (CBMC)
were isolated by Ficoll density gradient centrifugation. CD19 + B cells (>99% purity) and CD4 + T cells, (>95% purity) were magnetically purified using appropriate negative selection kits according to the manufacturer's protocol (Miltenyi Biotec, Bergisch Gladbach, Germany 
Reagents for functional assays
For BCR stimulation, affinity purified rabbit F (ab') 2 against human IgA+IgG+IgM (H+L) was used at 6.5µg/ml (anti-BCR, Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Human recombinant IL-21 (50ng/ml) was purchased from BioSource (Camarillo, CA, USA 
GrB ELISpot
Human GrB ELISpot kits were purchased from Gene-Probe Diaclone SAS (Besançon Cedex, France) and PVDF-bottomed 96-well plates from Millipore (Bedford, MA, USA). ELISpot assays were performed as recently described (15 For quantification of IL-2, supernatants from B cells and T cells co-cultured at a 1:1-ratio for 3 days were analyzed using a BioPlex-9 Plex Cytokine Assay Kit (BioRad Laboratories, Hercules, CA, USA) according to the manufacturer´s instructions. All incubations were performed at RT. Briefly, the anti-cytokine bead solution was diluted and 50µl were placed on 96-well Durapore membrane plates (Millipore, Billerica, MA). After washing by vacuum filtration, 50µl of undiluted supernatants and standards were placed into wells and incubated for 30min on a shaker. After washing, 25µl detection ab was added and incubated for another 30min while shaking. After washing, streptavidin-PE was added for 10min. Finally, plates were washed, resuspended in assay buffer and read on a flow cytometer (Luminex, Riverside, CA). Data were analyzed using Bio-Plex Manager software (Bio-Rad, Hercules, CA, USA).
Immunofluorescence microscopy
Formalin-fixed, paraffin-embedded cancer tissue sections (1µm) from various solid epithelial cancers including breast, cervical, ovarian, colorectal and prostate carcinomas were obtained from the local department of Pathology ( Table 1 Cy3-conjugated secondary abs as well as premature denaturation of ab binding sites by placing the heating step directly after binding of the primary anti-GrB and anti-IL-21 abs respectively. In this case, no binding of secondary biotinylated abs could be observed. For analysis, nuclei were stained with DAPI, sections were mounted in Vectashield mounting medium (Vector Laboratories Inc, Burlingame, CA, USA) and visualized using an Axioscope 2 fluorescence microscope (Zeiss, Göttingen, Germany).
Statistics
Data are expressed as mean values ± SEM unless stated otherwise. Statistical differences between the means of two data columns were asessed using the unpaired and paired Student's t-test as appropriate. Results with p-values <0.05 were considered statistically significant. pvalues were corrected using the Bonferroni method where applicable.
Results
Interleukin 21-activated B cells produce granzyme B and suppress CD4
+ T cell proliferation.
Recently, we found that the IL-2 family cytokine IL-21 can trigger B cells to secrete the serine protease GrB (15, 16) . Since expression of GrB by B cells is not accompanied by perforin expression, they may exhibit perforin-independent functions(23), such as the immunosuppressive capacity of T reg (17) (18) (19) . To test the hypothesis that GrB Fig. 2 ) or in the presence of unstimulated or IL-2-stimulated B cells (Fig. 1C, D) . B cells stimulated with IL-21 alone had a mild suppressive effect only, corresponding with a lower expression of GrB (Fig. 1C, D) . Both a GrB-neutralizing antibody and a specific GrB substrate inhibitor were able to rescue T cell proliferation (Fig. 1E, F) .
The lower proliferation of T cells in the presence of BCR-stimulated B cells is due to enhanced consumption of media with anti-BCR-induced B cell proliferation.
Inhibition of T cell proliferation by B cells involves transfer of active GrB to T cells and degradation of the T cell receptor ζ−chain, but not induction of T cell apoptosis.
Next, we characterized the underlying interactions between GrB + B cells and T cells. A potential impact of GrB on T cells may be induction of apoptosis by caspase cleavage.
Nevertheless, using FACS analysis we excluded that B cells stimulated in the presence of IL- 
12
21 ± anti-BCR were able to induce significant T cell apoptosis (Suppl. Fig. 3A, B) . A more recently identified GrB substrate is the ζ−chain of the T cell recpetor (TCR-ζ), which plays a role in delivering activation and growth signals to T cells (34) . To test the impact of B cellderived GrB on TCR-ζ we co-incubated CD3/CD28-activated CD4 + T cells in the presence or absence of B cells activated with IL-21 ± anti-BCR. B cells stimulated with IL-21 and anti-BCR, but not B cells stimulated with anti-BCR only, were able to strongly suppress TCR-ζ expression in co-incubated CD4 + T cells (Fig. 2B, C) . This effect was not seen in the absence of B cells (data not shown). More importantly, TCR-ζ expression in T cells was partly rescued by a GrB-neutralizing antibody (Fig. 2B, C) .
GrB expression by IL-21-stimulated B cells is part of a regulatory B cell phenotype.
As outlined above, we primarily described IL-21-induced B reg as cells able to express and secrete GrB (Fig. 1) , a capacity they appear to share with regulatory T cells (17) (18) (19) and regulatory dendritic cells (20) . To define in more detail the phenotype of IL-21-induced GrB + B cells, we tested a variety of surface antigens described in the past to characterize B reg (5, 6, 8, 9, 35) . These antigens include activation markers, molecules of the immunoglobulin superfamily, costimulatory molecules, enzymes and adhesion molecules. We found significant upregulation of several of these molecules in IL-21-stimulated GrB + B cells including CD38, CD1d, IgM, CD86, CD154, CD10 and CD20 (Fig. 3) . CD70 showed a higher expression in GrB + B cells as compared to unstimulated B cells, while CD24, CD27
and IgD exhibited no increase or even a decrease in GrB + B cells (Fig. 3) .
A frequently reported characteristic of B reg is the expression of IL-10, with such B cells often referred to as B10 cells (2, 5, 6) . Here, we demonstrate that healthy peripheral B cells stimulated with IL-21/anti-BCR also responded with the development of a small but significant population of B cells expressing IL-10 ( Fig. 4A, B ). This population did not occur in the presence of IL-2 nor in the absence of cytokines. Moreover, co-stimulation of B cells with IL-21/anti-BCR was able to induce IDO, another regulatory molecule previously described in dendritic cells (36) . Again, this effect was small but significant, and most pronounced in the presence of IL-21, but not with IL-2 or without cytokines (Fig. 4C, D) .
Importantly, after stimulation of B cells with IL-21 and anti-BCR, GrB not only was the first regulatory molecule expressed (Fig. 1) , but all additional regulatory molecules tested were primarily expressed on GrB + , but not on GrB -B cells (Suppl . Fig. 4 ). 
Since IL-21-activated GrB + B cells appear to express characteristic B reg markers, we also tested T reg -specific antigens. Regulatory T cells typically express high levels of CD25 and it was hypothesized that part of their inhibtory effect is effector T cell deprivation of IL-2 (37, 38) . IL-21-stimulated B cells indeed significantly upregulated surface CD25 (Fig. 4E, F) , and were able to capture free IL-2 from T cell/B cell co-cultures (Fig. 4G) . Nevertheless, we were not able to rescue the proliferative response of co-cultured T cells by retitrating recombinant IL-2 (Suppl. Fig. 5 ), indicating that IL-2 deprivation may not be the primary mechanism exhibited by human B reg . Finally, IL-21-activated B cells expressed increased levels of the T reg -specific Ig family member CD147(39) (Fig. 3) (Fig. 5A, B, C) . Moreover, we previously (Fig. 5D, E) suggests the additional involvement of toll-like receptors (TLR) like TLR7 or TLR9. Indeed, we found that inhibition of both TLR7 and TLR9 using specific inhibitory ODN(40) suppressed IL-21- Fig. 6 ).
GrB-expressing B cells and IL-21-expressing T cells reside in the microenvironment of various solid tumors
Although the regulation of immunity is important, its suppression may be undesired when the establishment of a robust immune response, for example against a tumor, is required. To evaluate whether B cells with a regulatory phenotype could play a role in the modulation of anti-tumor immune responses, we screened a variety of tumor tissue sections for GrB + B cells.
We found that GrB-expressing B cells reside within the microenvironment of different tumor types including breast, ovarian, cervical, colorectal and prostate carcinomas (Fig. 6A-F (Fig. 6G, H) . Importantly, we also detected IL-10-expressing CD19 + B cells in the same tumor tissues that contained GrB + B cells, suggesting that B cells with a regulatory phenotype in this tumor micorenvironment may express both IL-10 and GrB (Suppl. Fig. 7) . The exact phenotype of B reg is not clearly defined and multiple discrepancies exist between different studies(1, 2). A common finding in mice appears to be IL-10 secretion and expression of CD1d and CD5(5-7). These data were only partly confirmed in humans (8, 9) . A recent study described a human CD19 + CD24
hi CD38 hi B cell population with regulatory potential, which is functionally impaired in SLE patients (8) . This B cell population secreted IL-10, but did not express CD5. Of note, its regulatory capacity was dependent on CD86
expression, but only partially on IL-10 secretion, so that the authors postulated the existence of further soluble factors with regulatory potential. These results are complementary to our data showing that CD86 is strongly upregulated in IL-21-activated B reg and that the B reg identified in our study secrete several additional regulatory molecules. One of these molecules is CD25, which is also expressed on T reg (37, 38) . A recent study demonstrated the development of large, CD25 + B cells with regulatory potential after polyclonal activation with different TLR-agonistic stimuli (43) . Part of the regulatory effect identified in CD25-expressing B cells may therefore be due to IL-2 deprivation(37, 38). We further identified (C) Relative band intensities of TCR-ζ and β-actin were determined using Image J and ratios were calculated. Bar graphs show the ratios between TCR-ζ and β-actin band intensities. 
